SenesTech (NASDAQ:SNES) Cut to Hold at ValuEngine

SenesTech (NASDAQ:SNES) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Friday, June 7th, ValuEngine reports.

Shares of NASDAQ SNES traded up $0.22 during midday trading on Friday, hitting $1.80. The company had a trading volume of 444,320 shares, compared to its average volume of 114,326. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.83 and a quick ratio of 2.76. SenesTech has a twelve month low of $0.55 and a twelve month high of $1.95. The firm has a 50-day simple moving average of $1.53. The firm has a market cap of $39.49 million, a price-to-earnings ratio of -2.86 and a beta of 1.65.

SenesTech (NASDAQ:SNES) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The firm had revenue of $0.02 million during the quarter. SenesTech had a negative net margin of 3,908.08% and a negative return on equity of 186.65%. Research analysts forecast that SenesTech will post -0.19 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in SNES. Vanguard Group Inc raised its position in shares of SenesTech by 35.3% during the 3rd quarter. Vanguard Group Inc now owns 162,808 shares of the company’s stock worth $112,000 after buying an additional 42,500 shares in the last quarter. Virtu Financial LLC grew its stake in shares of SenesTech by 87.4% in the 1st quarter. Virtu Financial LLC now owns 56,447 shares of the company’s stock worth $69,000 after purchasing an additional 26,322 shares during the last quarter. Finally, Meitav Dash Investments Ltd. acquired a new position in shares of SenesTech in the 1st quarter worth approximately $81,000. Institutional investors own 7.73% of the company’s stock.

SenesTech Company Profile

SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.

Further Reading: What is Cost of Debt?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.